A meta-analysis of neoadjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancers / 南方医科大学学报
Journal of Southern Medical University
;
(12): 943-945, 2009.
Article
in Chinese
| WPRIM
| ID: wpr-268804
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of neoadjuvant chemotherapy combined with trastuzumab for HER2 positive breast cancers.</p><p><b>METHODS</b>PubMed online database, ASCO abstract database, SABCS abstract database, ESMO abstract database and CBMdisc database were searched for literatures related to trastuzumab in neoadjuvant chemotherapy for breast cancers. A meta-analysis was performed for retrieved literatures meeting the inclusion criteria.</p><p><b>RESULTS</b>Three clinical trials were included. Meta-analysis showed that compared to chemotherapy only, regimens combined with trastuzumab could significantly improved the pCR rate of HER2-positive breast cancers (RR=1.65, 95% CI 1.28-2.13, P<0.0001) without increasing the frequencies of cardiac toxicity (RR=1.16, 95% CI 0.82-1.64, P=0.41).</p><p><b>CONCLUSION</b>In neoadjuvant chemotherapy for HER2-positive breast cancers, chemotherapy combined with trastuzumab is superior to exclusive chemotherapy.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Breast Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Randomized Controlled Trials as Topic
/
Receptor, ErbB-2
/
Neoadjuvant Therapy
/
Therapeutic Uses
/
Drug Therapy
/
Antibodies, Monoclonal, Humanized
/
Trastuzumab
/
Genetics
Type of study:
Controlled clinical trial
/
Systematic reviews
Limits:
Female
/
Humans
Language:
Chinese
Journal:
Journal of Southern Medical University
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS